Hikma Pharmaceuticals
Company Details
Linkedin ID:
hikma-pharmaceuticals
Website:
Employees number:
10,222
Number of followers:
627,035
NAICS:
3254
Industry Type:
Homepage:
hikma.com
IP Addresses:
31
Company ID:
HIK_2329616
Scan Status:
Completed
Hikma Pharmaceuticals Company CyberSecurity Posture
hikma.com
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Hikma Pharmaceuticals A.I CyberSecurity Scoring
Hikma Pharmaceuticals Risk Score (AI oriented)Between 750 and 799
Hikma Pharmaceuticals
Updated:
- Powered by our proprietary A.I cyber incident model
- Insurance preferes TPRM score to calculate premium
Hikma Pharmaceuticals Global Score (TPRM)XXXX
Hikma Pharmaceuticals
- Instant access to detailed risk factors
- Benchmark vs. industry & size peers
- Vulnerabilities
- Findings
Hikma Pharmaceuticals Company CyberSecurity News & History
Past Incidents
0
Attack Types
0
No data available
Hikma Pharmaceuticals Company Scoring based on AI Models
Cyber Incidents Likelihood 3 - 6 - 9 months
A.I Risk Score Likelihood 3 - 6 - 9 months
Underwriter Stats for Hikma Pharmaceuticals
Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2025.
Incidents vs All-Companies Average (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2025.
Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2025.
Incident History — Hikma Pharmaceuticals (X = Date, Y = Severity)
Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries
Hikma Pharmaceuticals Company Subsidiaries
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Loading...
Hikma Pharmaceuticals Similar Companies
Sandoz
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health c
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working t
Astellas Pharma
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneer
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing t
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye ca
Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Tr
Merck Group
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trad
MANKIND PHARMA LTD
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing,
Ipca Laboratories Limited
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need
.png)
Hikma Pharmaceuticals CyberSecurity News
November 14, 2025 08:00 AM
Directors’ Deals: Hikma Pharma director eyes recovery
A downbeat trading statement on November 6 proved a bitter pill to swallow for shareholders in Hikma Pharmaceuticals.
November 06, 2025 08:00 AM
Hikma Pharmaceuticals shares slump as lowers mid-term outlook
Hikma Pharmaceuticals PLC on Thursday reduced medium term guidance and cut the top-end of its 2025 core operating profit view amid a delayed...
September 19, 2025 07:00 AM
Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company
Key Insights Institutions' substantial holdings in Hikma Pharmaceuticals implies that they have significant influence...
August 10, 2025 07:00 AM
One Hikma Pharmaceuticals Insider Raised Stake By 14% In Previous Year
LSE:HIK 1 Year Share Price vs Fair Value Explore Hikma Pharmaceuticals's Fair Values from the Community and select...
July 21, 2025 07:00 AM
Hikma Pharmaceuticals (LON:HIK) shareholders have earned a 8.3% CAGR over the last three years
By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at...
May 29, 2025 07:00 AM
Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’
Amman, Jordan – Hikma Pharmaceuticals PLC (Hikma, Company) is pleased to announce that Fitch has upgraded its long-term issuer default...
May 26, 2025 07:00 AM
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
The US Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection.
May 08, 2025 07:00 AM
Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case
Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a generic version...
March 08, 2025 08:00 AM
Hikma races to launch generic versions of blockbuster obesity drugs
Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year.
Frequently Asked Questions
Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
Hikma Pharmaceuticals CyberSecurity History Information
Official Website of Hikma Pharmaceuticals
The official website of Hikma Pharmaceuticals is http://www.hikma.com.
Hikma Pharmaceuticals’s AI-Generated Cybersecurity Score
According to Rankiteo, Hikma Pharmaceuticals’s AI-generated cybersecurity score is 769, reflecting their Fair security posture.
How many security badges does Hikma Pharmaceuticals’ have ?
According to Rankiteo, Hikma Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
Does Hikma Pharmaceuticals have SOC 2 Type 1 certification ?
According to Rankiteo, Hikma Pharmaceuticals is not certified under SOC 2 Type 1.
Does Hikma Pharmaceuticals have SOC 2 Type 2 certification ?
According to Rankiteo, Hikma Pharmaceuticals does not hold a SOC 2 Type 2 certification.
Does Hikma Pharmaceuticals comply with GDPR ?
According to Rankiteo, Hikma Pharmaceuticals is not listed as GDPR compliant.
Does Hikma Pharmaceuticals have PCI DSS certification ?
According to Rankiteo, Hikma Pharmaceuticals does not currently maintain PCI DSS compliance.
Does Hikma Pharmaceuticals comply with HIPAA ?
According to Rankiteo, Hikma Pharmaceuticals is not compliant with HIPAA regulations.
Does Hikma Pharmaceuticals have ISO 27001 certification ?
According to Rankiteo,Hikma Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Industry Classification of Hikma Pharmaceuticals
Hikma Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.
Number of Employees at Hikma Pharmaceuticals
Hikma Pharmaceuticals employs approximately 10,222 people worldwide.
Subsidiaries Owned by Hikma Pharmaceuticals
Hikma Pharmaceuticals presently has no subsidiaries across any sectors.
Hikma Pharmaceuticals’s LinkedIn Followers
Hikma Pharmaceuticals’s official LinkedIn profile has approximately 627,035 followers.
NAICS Classification of Hikma Pharmaceuticals
Hikma Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
Hikma Pharmaceuticals’s Presence on Crunchbase
Yes, Hikma Pharmaceuticals has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/hikma-pharmaceuticals.
Hikma Pharmaceuticals’s Presence on LinkedIn
Yes, Hikma Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/hikma-pharmaceuticals.
Cybersecurity Incidents Involving Hikma Pharmaceuticals
As of December 11, 2025, Rankiteo reports that Hikma Pharmaceuticals has not experienced any cybersecurity incidents.
Number of Peer and Competitor Companies
Hikma Pharmaceuticals has an estimated 5,412 peer or competitor companies worldwide.
Hikma Pharmaceuticals CyberSecurity History Information
How many cyber incidents has Hikma Pharmaceuticals faced ?
Total Incidents: According to Rankiteo, Hikma Pharmaceuticals has faced 0 incidents in the past.
What types of cybersecurity incidents have occurred at Hikma Pharmaceuticals ?
Incident Types: The types of cybersecurity incidents that have occurred include .
Incident Details
What are the most common types of attacks the company has faced ?
Additional Questions
.png)
Latest Global CVEs (Not Company-Specific)
Description
FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description
Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.
Risk Information
cvss3
Base: 9.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:H
Description
Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.
Risk Information
cvss3
Base: 8.2
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:N
Description
Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.
Risk Information
cvss3
Base: 8.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:H/A:L
Description
The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.
Risk Information
cvss3
Base: 5.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:R/S:U/C:H/I:L/A:N
Access Data Using Our API
Get company history
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?linkedin_id=hikma-pharmaceuticals' -H 'apikey: YOUR_API_KEY_HERE'
RapidWhat Do We Measure ?
Incident
Finding
Grade
Digital Assets
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
These are some of the factors we use to calculate the overall score:
Network Security
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
SBOM (Software Bill of Materials)
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
CMDB (Configuration Management Database)
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Threat Intelligence
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.
